Alpine Global Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Alpine Global Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,411	Closed	-$58K	–	269
2019 Q4	$58K	Buy	+15,411	New	+$72.1K	0.01%	386
2019 Q1	–	Sell	-10,374	Closed	-$20K	–	114
2018 Q4	$20K	Buy	+10,374	New	+$29.7K	0.01%	231
2016 Q3	–	Sell	-102,782	Closed	-$73K	–	106
2016 Q2	$73K	Buy	+102,782	New	+$82.8K	0.03%	148

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Alpine Global Management's CPRX Position: Q1 2020 in Review

Alpine Global Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2020, closing a stake of 15,411 shares — an estimated $58K sold.

Alpine Global Management first reported a position in CPRX in Q2 2016 and held it in 3 quarters. The position peaked at $73K in Q2 2016. 131 funds tracked by Wall St. Rank hold CPRX as of Q1 2020.

Alpine Global Management reported no remaining Catalyst Pharmaceutical position as of Q1 2020 after selling out during the quarter.
Alpine Global Management sold 15,411 Catalyst Pharmaceutical shares in Q1 2020, an estimated $58K.
Alpine Global Management first reported a position in Catalyst Pharmaceutical in Q2 2016 and held it in 3 quarters.
Alpine Global Management's Catalyst Pharmaceutical position peaked at $73K in Q2 2016.
131 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.